

## BIBLIOGRAPHIE

### Première Partie

- 1- DE LORGERIL M. : *Dites à votre médecin que le cholestérol est innocent*. Editions Thierry Souccar, 2007.
- 2- TAUBES G. : *Do we really know what makes US Healthy?* The New York Times September 2007.
- 3- MELANDER H. ET AL. : *Evidence b(i)ased medicine : selective reporting from studies sponsored by pharmaceutical industry*. BMJ 2003;326:1171-3.
- 4- FUNCK-BRUNTANO C., ROSENHEIM M. : *La pensée critique en médecine, une nécessité*. Le Monde du 10 Mars 2007.
- 5- WOOD S. : *Both researchers and journals are to blame for inconsistent disclosure of conflicts of interest*. Heartwire 2008 Medscape May 7 2008.
- 6- WEINFURT KP. ET AL. : *Consistency of financial interest disclosure in the biomedical literature*. PlosOne 2008;3:e2128.
- 7- HEAVEY S. : *Cholesterol scientist balked at delay; lawmaker*. Reuters April 1, 2008.
- 8- MAMOU Y. : *Pfizer mis en cause au Nigeria*. Le Monde du 24 Mai 2007.
- 9- BLANCHARD S. : *Les mensonges de l'industrie agroalimentaire passés au crible*. Le Monde du 19 Mai 2007.
- 10- SMITH R. : *Medical journals and pharmaceutical companies: uneasy bedfellows*. BMJ 2003;326:1202-5.

- 11- CLASSEN D. : *Medication safety. Moving from illusion to reality.* JAMA 2003;289:1154-6.
- 12- SUCKLING K. : *The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.* Expert Opin Pharmacother. 2008 May;9(7):1067.
- 13- KASTELEIN JJ. ET AL. : *Simvastatin with or without ezetimibe in familial hypercholesterolemia.* N Engl J Med. 2008 Apr 3;358(14):1431-43.
- 14- GREENLAND P., LLOYD-JONES D. : *Critical lessons from the ENHANCE trial.* JAMA. 2008 Feb 27;299(8):953-5.
- 15- BROWN BG., TAYLOR AJ. : *Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?* N Engl J Med. 2008 Apr 3;358(14):1504-7.
- 16- O'RIORDAN M. : *Congress Continues to Probe Merck and Schering-Plough: Angry Emails Highlight ENHANCE Controversy.* Heartwire 2008 Medscape April 1, 2008.
- 17- O'RIORDAN M. : *ENHANCE Published, Presented, Discussed, and Debated: Experts Mull Over What the Findings Mean.* Heartwire 2008 Medscape March 1, 2008.
- 18- O'RIORDAN M. : *Questioning the Importance of LDL Cholesterol: The ENHANCE Fallout.* Heartwire 2008 Medscape January 22, 2008.
- 19- BERENSON A. : *New questions on treating cholesterol.* New York Times, January 17, 2008. Available at: <http://www.nytimes.com>.
- 20- CAREY J. : *Do cholesterol drugs do any good?* BusinessWeek, January 17, 2008. Available at: <http://www.businessweek.com>.

BIBLIOGRAPHIE

21- SCHWARTZ D. : *Le jeu de la science et du hasard*. La statistique et le vivant. Flammarion, 1994.

22- ESCHWÈGE D. ET AL. : *Essais thérapeutiques ; mode d'emploi*. Editions Inserm.

23- TAUBES G. : *Good calories, bad calories*. Alfred Knopf Editions. New York 2007.

24- SHAH PK ET AL. : *Vaccination for atherosclerosis: a novel therapeutic paradigm*. Expert Rev Vaccines 2004 ; 3: 711-716.

25- MAMOU Y. : *Glaxo intimidé par les prix*. Le Monde du 16 Mars 2007.

26- LEDFORD H. : *Drug markers questioned*. Nature 2008 Apr 3;452(7187):510-1.

27- COUZIN J. : *Drug testing. Regulators talk up plans for drug biomarkers ...* Science 2004 Nov 12;306(5699):1119.

28- MEYERSON LJ. ET AL. : *Quality control of oncology clinical trials*. Hematol Oncol Clin North Am. 2000 Aug;14(4):953-71.

29- HEART PROTECTION STUDY COLLABORATIVE GROUP : *MRC:BHF heart protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial*. Lancet 2002;360:7-22.

30- SEVER PS. ET AL. : *Prevention of coronary and stroke events with atorvastatin in hypertensive patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial*. Lancet 2003;361:1149-58.

31- BERO L. ET AL. : *Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others*. PLoS Med 2007;4:e184.

## Deuxième Partie

1- STEINBERG D ET AL. : *Beyond cholesterol. Modifications of low-density lipoproteins that increase its atherogenicity*. N Engl J Med 1989;320:915.

2- ROSS R. : *Atherosclerosis: an inflammatory disease*. N Engl J Med 1999;340:115-26.

3- HANSSON GK. : *Inflammation, atherosclerosis, and coronary artery disease*. N Engl J Med 2005 ; 352:1685-1695.

4- HANSSON GK., LIBBY P. : *The immune response in atherosclerosis: a double-edged sword*. Nat Rev Immunol 2006 ; 6:508-519.

5- ZHOU X. ET AL. : *Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice*. Circulation 2000 ; 102: 2919-2922.

6- GEORGE J. ET AL. : *Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice*. J Am Coll P Cardiol 2001 ; 38: 900-905.

7- HJERMANN I. ET AL. : *Effect of diet and smoking intervention on the incidence of coronary heart disease*. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981 Dec 12;2(8259):1303.

8- HJERMANN I. ET AL. : *Oslo Study Diet and Antismoking Trial. Results after 102 months*. Am J Med. 1986 Feb 14;80(2A):7-11.

## BIBLIOGRAPHIE

- 9- DE LORGERIL M., SALEN P. : *Selenium and antioxidant defenses as major mediators in the development of chronic heart failure*. Heart Fail Rev 2006;11:13-17.
- 10- DE LORGERIL M. ET AL. : *Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study*. Circulation 1999;99:779-85.
- 11- BURR ML. ET AL. : *Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction : Diet And Reinfarction Trial (DART)*. Lancet 1989;2:757-61.
- 12- DE LORGERIL M. ET AL. : *Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease*. Lancet 1994;343:1454-9.
- 13- GISSI-PREVENZIONE INVESTIGATORS : *Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial*. Lancet 1999;354:447-55.
- 14- CAMPOS H. ET AL. : *Alpha-linolenic acid and risk of nonfatal acute myocardial infarction*. Circulation 2008; 10.1161/CIRCULATIONAHA.107.762419.
- 15- HARRIS WS. : *Cardiovascular risk and alpha-linolenic acid*. Circulation 2008; DOI: 1161/CIRCULATIONAHA.108.791467.
- 16- MIURA K. ET AL. : *Relationship of dietary linoleic acid to blood pressure*. Hypertension 2008; 52; DOI: 10.1161/HYPERTENSIONAHA.108.112383.
- 17- WEAVER KL. ET AL. : *The content of favorable and unfavorable polyunsaturated fatty acids found in commonly eaten fish*. J Am Diet Assoc 2008; 108:1178-1185.

- 18- VAN HORN L. : *Fishing for answers*. J Am Diet Assoc 2008; 108: 110.
- 19- DE LORGERIL M. ET AL. *The diet heart hypothesis in secondary prevention of coronary heart disease*. Eur Heart J 1997;18:14-18.
- 20- DE LORGERIL M., SALEN P. : *Cholesterol lowering and mortality: time for a new paradigm?* Nutr Metab Cardiovasc Dis 2006;16:387-90.
- 21- ALBERT CM. ET AL. : *Prospective study of C-Reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death*. Circulation 2002;105:2595-9.
- 22- ALBERT CM. ET AL. : *Prospective study of sudden cardiac death among women in the United States*. Circulation 2003;107:2096-2101.
- 23- DE LORGERIL M. ET AL. : *Dietary prevention of sudden cardiac death*. Eur Heart J 2002;23:277-85.
- 24- ZHENG ZJ. ET AL. : *Sudden cardiac death in the United States, 1989 to 1998*. Circulation 2001;104:2158-63.
- 25- LEAF A. ET AL. : *Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils*. Circulation 2003;107:2646.
- 26- KRIS-ETHERTON PM. ET AL. : *Polyunsaturated fatty acids in the food chain in the United States*. Am J Clin Nutr 2000;71(suppl):179S-88S.
- 27- DE CATERINA A., ZAMPOLI R. : *From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation*. N Engl J Med. 2004;350:4-7.

## BIBLIOGRAPHIE

- 28- KRIS-ETHERTON P. ET AL. : *Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on cardiovascular disease.* Circulation 2001;103:1823-5.
- 29- KANNEL WB. ET AL. : *Factors of risk in the development of coronary heart disease--six year follow-up experience.* The Framingham Study. Ann Intern Med. 1961 Jul;55:33-50.
- 30- Dawber TR. ET AL. : *Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study.* Am J Public Health Nations Health. 1959 Oct;49:1349-56.
- 31- DAWBER TR. ET AL. : *Dietary assessment in the epidemiologic study of coronary heart disease: the Framingham study.* II. Reliability of measurement. Am J Clin Nutr. 1962 Sep;11:226-34.
- 32- KANNEL WB. ET AL. : *Serum cholesterol, lipoproteins, and the risk of coronary heart disease.* The Framingham study. Ann Intern Med. 1971 Jan;74(1):1-12.
- 33- KEYS A. ET AL. : *The diet and 15-year death rate in the Seven Countries Study.* Am J Epidemiol 1986;124:903-915.
- 34- KEYS A. : *Mediterranean diet and public health: personal reflections.* Am J Clin Nutr. 1995 Jun;61(6 Suppl):1321S-1323S.
- 35- KEYS A. ET AL. : *The seven countries study: 2,289 deaths in 15 years.* Prev Med. 1984 Mar;13(2):141-54.
- 36- KEYS A. ET AL. : *The diet and 15-year death rate in the seven countries study.* Am J Epidemiol. 1986 Dec;124(6):903-15.

- 37- TRICHOPOULOU A. ET AL. : *Adherence to a Mediterranean diet and survival in a Greek population.* N Engl J Med 2003;348:2599-2608.
- 38- KAFATOS A. ET AL. : *Heart disease risk-factor status and dietary changes in the Cretan population over the past 30 years: the Seven Countries Study.* Am J Clin Nutr 1997; 65: 1882-1886.
- 39- TRICHOPOULOU A. ET AL. : *Mediterranean diet and survival among patients with coronary heart disease in Greece.* Arch Intern Med 2005;165:929-35.
- 40- CHRYSOHOOU C. ET AL. : *Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study.* J Am Coll Cardiol 2004;44:152-8.
- 41- ESPOSITO K. ET AL. : *Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial.* JAMA. 2004;292:1440-6.
- 42- PASCHOS GK. ET AL. : *Background diet influences the anti-inflammatory effect of alpha-linolenic acid in dyslipidaemic subjects.* Br J Nutr 2004;92:649-55 .
- 43- RENAUD S., DE LORGERIL M. : *The French paradox for coronary heart disease.* Lancet 1992;339:1523-6.
- 44- DE LORGERIL M., SALEN P. : *Wine ethanol, platelets, and Mediterranean diet.* Lancet 1999 ; 353:1067.
- 45- DE LORGERIL M., SALEN P. : *Is alcohol anti-inflammatory in the context of coronary heart disease?* Heart 2004;90:355-7.



BIBLIOGRAPHIE

- 46- MRFIT INVESTIGATORS : *The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease.* JAMA. 1976 Feb 23;235(8):825-7.
- 47- MANDRIOTA R. ET AL. : *Nutrition intervention strategies in the Multiple Risk Factor Intervention Trial (MRFIT).* J Am Diet Assoc. 1980 Aug;77(2):138-40.
- 48- BENFARI RC. : *The multiple risk factor intervention trial (MRFIT). III. The model for intervention.* Prev Med. 1981 Jul;10(4):426-42.
- 49- CUTLER JA. ET AL. : *Coronary heart disease and all-causes mortality in the Multiple Risk Factor Intervention Trial: subgroup findings and comparisons with other trials.* Prev Med. 1985 May;14(3):293-311.
- 50- STAMLER J. ET AL. : *Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).* JAMA. 1986 Nov 28;256(20):2823-8.
- 51- MARTIN MJ. ET AL. : *Serum cholesterol, blood pressure and mortality: implication from a cohort of 361 662 men.* Lancet saturday 25 october 1986.
- 52- THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL RESULTS. I. *Reduction in incidence of coronary heart disease.* JAMA. 1984 Jan 20;251(3):351-64.
- 53- DOWNS JR. ET AL. : *Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.* JAMA. 1998 May 27;279(20):1615-22.

54- SHEPHERD J. ET AL. : *Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.* N Engl J Med. 1995 Nov 16;333(20):1301-7.

55- FORD I. ET AL. : *Long-term follow-up of the West of Scotland Coronary Prevention Study.* N Engl J Med. 2007 Oct 11;357(15):1477-86.

56- RUBINS HB. ET AL. : *Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.* N Engl J Med. 1999 Aug 5;341(6):410-8.

57- DE LORGERIL M. ET AL. : *Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction.* Circulation 2002;106:1465-9.

### Troisième Partie

1- DE LORGERIL M. *Dites à votre médecin que le cholestérol est innocent.* Editions Thierry Souccar, 2007.

2- ABRAMSON J. ET AL. : *Are lipid-lowering guidelines evidence-based ?* Lancet 2007;369, January 20.

3- FIGNONE M. ET AL. : *Use of lipid-lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials.* BMJ 2000;321:983-6.

4- PSATY BM. ET AL. : *Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment.* JAMA 2008;299:1813-7.

5- ROSS JS. ET AL. : *Guest authorship and ghostwriting in publications related to rofecoxib.* JAMA 2008;299:1800-12.

BIBLIOGRAPHIE

- 6- ANONYME. : *Cash interests taint drug advice*. Nature 20 octobre 2005.
- 7- MELANDER H. ET AL. : *Evidence b(i)ased medicine : selective reporting from studies sponsored by pharmaceutical industry*. BMJ 2003;326:1171-3.
- 8- AMARENCO P. ET AL. : *Statins in Stroke Prevention*. Future Lipidol. 2008;3(3):319-325.
- 9- PROSPECTIVE STUDIES COLLABORATORS : *Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths*. Lancet 2007;370, December 1.
- 10- BAIGENT C. ET AL. : *Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins*. Lancet 366, 1267-1278 (2005).
- 11- GO AS. ET AL. : *Statin therapy and risk of death and hospitalisation in chronic heart failure*. JAMA 2006;296:2105-11.
- 12- KJEKHUS J. ET AL. : *Rosuvastatin in older patients with systolic heart failure*. N Engl J Med November 29,2007.
- 13- BARTER P. ET AL. : *HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events*. N Engl J Med 2007;357:13-9.
- 14- BARTER PJ. ET AL. : *Effects of torcetrapib in patients at high risk for coronary events*. N Engl J Med 2007;357:1002-9.
- 15- CHOLESTEROL TREATMENT TRIALISTS' COLLABORATORS : *Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins*. Lancet 2008;371, January 12.

- 16- WANNER C. ET AL. : *Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis*. N Engl JMed 2005;353 July 21.
- 17- KNOPP RH. ET AL. : *Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes*. Diabetes care 2006;29:1478-85.
- 18- LAROSA JC. ET AL. ; *for the Treating to New Target (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease*. N. Engl. J. Med. 352, 1425-1435 (2005).
- 19- COLHOUN HM. ET AL.: *Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial*. Lancet 364, 685-696 (2004).
- 20- SEVER PS. ET AL. : *Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial*. Lancet 361, 1149-1158 (2003).
- 21- HEART PROTECTION STUDY COLLABORATIVE GROUP : *MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial*. Lancet 361, 2005-2016 (2003).
- 22- AMARENCO P. ET AL. FOR THE SPARCL INVESTIGATORS : *High-dose atorvastatin after stroke or transient ischemic attack*. N. Engl. J. Med. 355(6), 549-555 (2006).

## BIBLIOGRAPHIE

23- CANNON CP. ET AL. : *Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes*. N. Engl. J. Med. 350, 1495-1504 (2004).

24- PEDERSEN TR. ET AL. : *High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial*. JAMA 294, 2427-2445 (2005).

25- KOREN MJ. AND HUNNINGHAKE DB. ON BEHALF OF THE ALLIANCE INVESTIGATORS : *Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study*. J. Am. Coll. Cardiol. 44, 1772-1779 (2004).

26- SHEPHERD J. ET AL. : *Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial*. Lancet 2002;360:1623-30.

27- THE ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP : *Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT)*. JAMA 2002;288:2998-3007.

28- WALSH JM. ET AL. : *Drug treatment of hyperlipidemia in women*. JAMA 2004;291:2243-49.

29- SCHWARZ GG. ET AL. : *Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial*. JAMA 2001;285:1711-8.

30- CANNON CP. ET AL. : *Intensive versus moderate lipid lowering with statins after acute coronary syndromes*. N Engl J Med 2004;350:1495-1504.

- 31- WATERS D. : *Statins in the Prevention and Treatment of Stroke*. Medscape Cardiology. 2006;10(1).
- 32- AMARENCO P. ET AL. : *Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis*. Stroke. 2004;35:2902-2909.
- 33- SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S) GROUP : *Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease*. Lancet. 1994;344:1383-1389.
- 34- SACKS FM. ET AL. : *Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels*. N Engl J Med. 1996;335:1001-1009.
- 35- THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP : *Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a board range of initial cholesterol levels*. N Engl J Med. 1998;339:1349-1357.
- 36- NEWMAN C. ET AL. : *Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients*. Am J Cardiol. 2006;97:61-67.
- 37- FONOROW G. ET AL. : *Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3*. Circulation. 2001;103:38-44.
- 38- BRIEL M. ET AL. : *Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials*. JAMA. 2006;295:2046-2056.

## Quatrième Partie

- 1- NEWMAN TB. ET AL. : *Carcinogenicity of lipid-lowering drugs*. JAMA. 1996 Jan 3;275(1):55-60.
- 2- SHEPHERD J. ET AL. : *Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial*. Lancet 2002;360:1623-30.
- 3- SMITH R. : *Medical journals and pharmaceutical companies: uneasy bedfellows*. BMJ 2003;326:1202-5.
- 4- WENGER NK. ET AL. : *Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease*. Ann Intern Med. 2007 Jul 3;147(1):1-9.
- 5- HUNT D. ET AL. : *Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial*. Ann Intern Med. 2001 May 15;134(10):931-40
- 6- ALSHEIKH-ALI AA. ET AL. : *Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials*. J Am Coll Cardiol. 2007 Jul 31;50(5):409-18.
- 7- CLASSEN D. : *Medication safety. Moving from illusion to reality*. JAMA 2003;289:1154-6.
- 8- DALE KM. ET AL. : *Statins and cancer risk: a meta-analysis*. JAMA 2006; 295: 74-80.
- 9- BROWNING DR ET AL. *Statins and risk of cancer: a systematic review and meta-analysis*. Int J Cancer 2006; 120: 833-843.

10- BAIGENT C. ET AL. : *Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins*. Lancet 2005; 366: 1267-1278.

11- FORD I. ET AL. : *Long-term follow-up of the West of Scotland Coronary Prevention Study*. N Engl J Med 2007; 357: 1477-1486.

12- HENNEKENS CH. ET AL. : *Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines*. MedGenMed 2006; 8: 54.

13- COLLI JL. ET AL. : *High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States*. Urol Oncol, 2008.

14- CARRUBA G. : *Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario*. J Cell Biochem 2007; 102: 899-911.

15- HALL SA. ET AL. : *Do statins affect androgen levels in men? Results from the Boston Area Community Health Survey*. Cancer Epidemiol Biomarkers Prev 2007 ; 16: 1587-1594.

16- DOBS AS. ET AL. : *Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients*. Metabolism 2000; 49: 115-121.

17- MELANDER H. ET AL. : *Evidence based medicine : selective reporting from studies sponsored by pharmaceutical industry*. BMJ 2003;326:1171-3.

18- MULDOON MF. ET AL. : *Effects of lovastatin on cognitive function and psychological well-being*. Am J Med. 2000 May;108(7):538-46.



BIBLIOGRAPHIE

- 19- MULDOON MF. ET AL. : *Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults.* Am J Med. 2004 Dec 1;117(11):823-9.
- 20- HARRIS JL. ET AL. : *Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients.* Prostaglandins Leukot Essent Fatty Acids. 2004 Oct;71(4):263-9.
- 21- DE LORGERIL M. ET AL. : *Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.* Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):36-41.
- 22- DE LORGERIL M. ET AL. : *Cholesterol lowering and mortality: time for a new paradigm ?* Nutr Metab Cardiovasc Dis. 2006 Sep;16(6):387-90.
- 23- DE LORGERIL M. ET AL. : *Lipid-lowering drugs and homocysteine.* Lancet. 1999 Jan 16;353(9148):209-10.
- 24- DE LORGERIL M. ET AL. : *Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.* J Heart Lung Transplant. 1996 May;15(5):539-40.
- 25- CONKLIN SM. ET AL. : *Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers.* Psychiatry Res. 2007 Jul 30;152(1):1-10.
- 26- DE LORGERIL M. ET AL. : *Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.* J Cardiovasc Pharmacol. 1999 Mar;33(3):473-8.
- 27- BECK M. : *Can a drug that help hearts be harmful to the brain ?* The Wall Street Journal February 12 2008.

- 28- BAYTAN SH. ET AL. : *Simvastatin impairs spatial memory in rats at a specific dose level*. Tohoku J Exp Med 2008;214:341-9.
- 29- WAGSTAFF LR. ET AL. : *Statin-associated memory loss: analysis of 60 case reports and review of literature*. Pharmacotherapy 2003;23:871-80.
- 30- GOLOMB BA. ET AL. : *Conceptual foundations of the UCSD statin study*. Arch Intern Med 2004;164:153-62.
- 31- FREUND-LEVI Y. ET AL. : *Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial*. Arch Neurol. 2006 Oct;63(10):1402-8.
- 32- CHIU CC. ET AL. : *The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study*. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 25.
- 33- SCHAEFER EJ. ET AL. : *Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study*. Arch Neurol. 2006 Nov;63(11):1545-50.
- 34- HEUDE B. ET AL. : *Cognitive decline and fatty acid composition of erythrocyte membranes--The EVA Study*. Am J Clin Nutr. 2003 Apr;77(4):803-8.
- 35- BEYDOUN MA. ET AL. : *Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study*. Am J Clin Nutr. 2007 Apr;85(4):1103-11.
- 36- DULLEMEIJER C. ET AL. : *n 3 fatty acid proportions in plasma and cognitive performance in older adults*. Am J Clin Nutr. 2007 Nov;86(5):1479-85.

## Cinquième Partie

1- VERMA S. ET AL. : *C-reactive protein comes of age*. Nat Clin Pract Cardiovasc Med 2005; 21: 29-36.

2- TJØNNA AE. ET AL. : *Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome*. A pilot study. Circulation. 2008; DOI: 10.1161/CIRCULATIONAHA.108.772822.

3- ABRAMSON J. : *Overdosed America. The broken promise of American medicine*. New York: HarperCollins, 2004

4- KIM HH. ET AL. : *Eicosapentaenoic acid inhibits TNF- $\alpha$ -induced matrix metalloproteinase-9 expression in human keratinocytes, HaCaT cells*. Biochem Biophys Res Commun. 2008 Apr 4;368(2):343-9.

5- DELBOSC S. ET AL. : *The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9*. Am J Pathol. 2008 May;172(5):1430-40.

6- OAK MH. ET AL. : *Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells*. Circulation. 2004 Sep 28;110(13):1861-7.

7- PEREZ MA. ET AL. : *Dietary docosahexaenoic acid alters pregnant rat reproductive tissue prostaglandin and matrix metalloproteinase production*. J Nutr Biochem. 2006 Jul;17(7):446-53.

8- KIM HH. ET AL. : *Eicosapentaenoic acid inhibits UV-induced MMP-1 expression in human dermal fibroblasts*. J Lipid Res. 2005 Aug;46(8):1712-20.

- 9- MCCABE AJ. ET AL. : *The effect of eicosapentanoic acid on matrix metalloproteinase gene expression.* *Lipids.* 1999;34 Suppl:S217-8.
- 10- DE LORGERIL M., SALEN P. : *Is alcohol anti-inflammatory in the context of coronary heart disease ?* *Heart.* 2004;90:355-7.
- 11- LEMAITRE RN. ET AL. : *Cell membrane trans-fatty acids and the risk of primary cardiac arrest.* *Circulation* 2002;105:697-701.
- 12- GUIRAUD A. ET AL. : *Cardioprotective effect of chronic low dose ethanol drinking. Insights into the concept of ethanol preconditioning.* *J Mol Cell Cardiol* 2006.
- 13- SISCOVICK DS. ET AL. : *Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.* *JAMA* 1995;274:1363-67.
- 14- ALBERT CM. ET AL. : *Fish consumption and the risk of sudden cardiac death.* *JAMA* 1998;279:23-28.
- 15- ALBERT CM. ET AL. : *Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians.* *Circulation* 1999;100:944-50.
- 16- HAMBRECHT R. ET AL. : *Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure.* *Circulation.* 1998 Dec 15;98(24):2709-15.
- 17- HAMBRECHT R. ET AL. : *Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure.* *J Am Coll Cardiol.* 1997 Apr;29(5):1067-73.

18- HAMBRECHT R. ET AL. : *Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles.* J Am Coll Cardiol. 1995 May;25(6):1239-49.

## Conclusion

1. STOSSEL TP. : *Response to AMA's Council on Ethical and Judicial Affairs draft report on "Ethical Guidance for Physicians and the Profession with Respect to Industry Support for Professional Education in Medicine."* Medscape J Med. 2008;10:137.

2. STOSSEL T. : *Regulating academic-industry research relationships -- solving problems or stifling progress.* N Engl J Med. 2005;353:1060-1065.

3. STOSSEL TP. : *Divergent views on managing clinical conflicts of interest.* Mayo Clin Proc. 2007;82:1013-1014.

4. ABRAMSON J. : *Overdosed America: The Broken Promise of American Medicine.* New York: HarperCollins; 2004.

5. ANGELL M. : *The Truth About the Drug Companies: How They Deceive Us and What to Do About it.* New York: Random House; 2004.

6. KASSIRER JP. : *On the Take: How Medicine's Complicity With Big Business Can Endanger Your Health.* New York: Oxford University Press; 2005.

7. BRODY H. : *Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry.* Lanham, MD: Rowman and Littlefield; 2007.

8. AVORN J. : *Powerful Medicines: The Benefits, Risks and Costs of Prescription Drugs.* New York: Knopf; 2004.

9. TURNER EH. ET AL. : *Selective publication of antidepressant trials and its influence on apparent efficacy*. N Engl J Med. 2008;358:252-260.
10. ABOUD L. : *Stung by public distrust, drug makers seek to heal image*. Wall Street Journal. 2005;(August 26):B1.
11. ERDE EL. : *Conflicts of interest in medicine: a philosophical and ethical morphology*. In: Speece RG, Shimm DS, Buchanan AE (eds). *Conflicts of Interest in Clinical Practice and Research*. New York: Oxford University Press; 1996.
12. SCHAFER A. : *Biomedical conflicts of interest: a defence of the sequestration thesis -- learning from the cases of Nancy Olivieri and David Healy*. J Med Ethics. 2004;30:8.